Japan Gabapentin Market Insight
Published: 29 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The Japan Gabapentin Market will grow at a rate of 6.50% due to rising demand for effective neuropathic pain therapies, increasing prevalence of postherpetic neuralgia and diabetic neuropathy, an expanding super-aged demographic, and the widespread clinical adoption of non-opioid anticonvulsant formulations in hospital and outpatient care settings.
Japan Gabapentin Market Insights Forecasts to 2035
- The Japan Gabapentin Market Size Was Estimated USD 79.1 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.50% from 2025 to 2035
- The Japan Gabapentin Market Size is Expected to rise around USD 148.5 Million by 2035
Notable Insights for the Japan Gabapentin Market
- Segmentation on the basis of Product Type indicates that Capsules and Oral Tablets dominate Japan market in 2025 with 52% share across retail and hospital pharmacy distribution channels.
- Segmentation on the basis of Application indicates that Neuropathic Pain, Diabetic Neuropathy and Epilepsy Treatment segment dominates Japan Gabapentin Market 2025 with 56% share, driven by rising chronic pain management demand.
- World-wide projected revenue of Pfizer Inc. in fiscal year 2025 would be around $61.0 billion, owing to high demand for central nervous system therapies, pain management formulations, and established prescription brands.
- It is expected that increasing modernization in neurological care, expansion of geriatric health services, and adoption of non-opioid pain management protocols would contribute in driving the growth of the market, where gabapentin formulations offer pain score reduction up to 34%, and minimize adverse central side effects up to 27%.
Download the eBook (ToC)
Why Buy This Report
- Gives an in-depth analysis of the impact of trends in neuropathic pain management, modernization in clinical neurology practice, and development in oral drug delivery technology on the Japan Gabapentin Market growth.
- Provides strategic insights regarding technology innovation such as extended-release formulation technology, patient-compliant disintegrating tablets, bioequivalence enhancement systems, and real-time therapeutic drug monitoring technology.
- Assists players to analyze competitive benchmarking, investment in pharmaceutical manufacturing, generic drug formulation in domestic facilities, and channel expansion in hospital pharmacies by major central nervous system drug suppliers.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Gabapentin Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Gabapentin Market
- Pfizer Inc.
- Sawai Pharmaceutical Co., Ltd.
- Nichi-Iko Pharmaceutical Co., Ltd.
- Towa Pharmaceutical Co., Ltd.
- Viatris Inc.
- Teva Takeda Pharma Ltd.
- Daiichi Sankyo Company, Limited
- Eisai Co., Ltd.
- Meiji Seika Pharma Co., Ltd.
- Apotex Inc.
Recent Developments:
- In January 2026, Towa Pharmaceutical Co., Ltd. introduced extended-release gabapentin tablet formulations integrated with specialized film-coating technology for improved patient compliance in chronic neuropathic pain management.
- In November 2025, Sawai Pharmaceutical Co., Ltd. launched next-generation generic gabapentin oral doses optimized for elderly clinical care, diabetic neuropathy treatment, and high-precision pain management applications.
Market Segmentation:
Japan Gabapentin Market, By Product Type
- Capsules
- Tablets
- Oral Solutions
- Extended-Release Formulations
- Combination Pain Therapies
Japan Gabapentin Market, By Technology
- Sustained-Release Drug Delivery
- Micro-Encapsulation Technology
- Solid Dispersion Systems
- Targeted Enteric Coating Formulations
- Automated Precision Dosage Manufacturing
Japan Gabapentin Market, By Application
- Neuropathic Pain
- Diabetic Neuropathy
- Epilepsy & Partial Seizures
- Postherpetic Neuralgia
- Restless Legs Syndrome
Expert Views:
The market for gabapentin in Japan will grow owing to the rise in the demand for non-opioid pain relief solutions, the growing number of geriatric care facilities, and increasing demand for specialized neuropathic pain and epilepsy treatments. The inclusion of extended-release delivery systems, advanced bioequivalence drug formulations, and high-precision quality control standards will enhance operational efficiency and boost the demand for gabapentin in the Japanese market.
Author: Govind and Krishna By Decisions Advisors and Consulting